Irulya Therapeutics Inc IRLA

$39.80 +0.02 (0.05%)

Valuation

Market cap
40,480,000
Revenue TTM
$0
Net income TTM
$-83,980,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
55,300
Avg volume
61,696
Day's range
$37.20 – $40.43
Shares out
1,017,000
Stochastic %K
71%
Beta
1.78
Analysts
Moderate Buy
Price target
$75.88

Price

Company profile

IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations i...

Show more

IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene. Its AIDE technology platform is a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells and consists of automated equipment, the RCL, a sterile single-use consumable treatment kit comprising medical device kits, syringe kits, and process solutions. IRulya Therapeutics Inc. was formerly known as Quince Therapeutics, Inc. and changed its name to IRulya Therapeutics Inc. in October 2026. The company was incorporated in 2012 and is headquartered in New Haven, Connecticut.

Industry
Biotechnology
Sector
Healthcare
Website
https://irulya.com
Address
101 College Street, Suite 210, New Haven, United States

Latest news

No headlines yet.